GLPBio

Maribavir

Catalog No.: GC10390Purity:>98.00%Synonyms: 1263W94; BW1263W94; GW257406X
COASDSData Sheet
Maribavir هو مثبط قوي لفسفرة هيستون محفز بواسطة pUL97 من النوع البري في المختبر ، مع IC50 من 3 نانومتر

المنتجات مخصصة للاستخدام البحثي فقط، وليست للاستخدام البشري. نحن لا نبيع للمرضى.

Maribavir
Cas No.: 176161-24-3
10mM (in 1mL DMSO)In Stock
$122.00
1
1mgIn Stock
$52.00
1
5mgIn Stock
$111.00
1
10mgIn Stock
$179.00
1
25mgIn Stock
$322.00
1
50mgIn Stock
$447.00
1
100mgIn Stock
$620.00
1
200mgIn Stock
$853.00
1
Tel: (909) 407-4943 / (909) 689-7124Email: sales@glpbio.com

المراجع (Citations)

لا تتوفر حاليًا مراجع لهذا المنتج. فيما يلي مجموعة مختارة من المنشورات التي تستشهد بمنتجات GlpBio.
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

الوصف (Description)

Maribavir is an orally active benzimidazole riboside antiviral agent. Maribavir competitively inhibits CMV pUL97 kinase activity (IC50=3nM). Maribavir blocks viral DNA replication, capsid formation, and nuclear egress. Maribavir retains activity against some traditional anti-CMV drug-resistant strains. Maribavir is used for refractory/resistant cytomegalovirus infection after transplantation and related research[1-4].

In vitro, human embryonic lung fibroblasts were treated with 0-100μM maribavir for 0-16 days. Maribavir inhibited cytomegalovirus replication yield measured by reporter gene SEAP expression[5]. MRC-5 cells infected with human cytomegalovirus were treated with 0.1-40μM maribavir for 24-96 hours. Maribavir reduced viral DNA accumulation and decreased viral titers[6]. Human foreskin fibroblasts were treated with 1-7μM maribavir for 6 days. Maribavir inhibited human cytomegalovirus AD169 strain replication[7].

In vivo, Sprague-Dawley rats were orally administered 0-400mg/kg/day Maribavir once daily for 1 month. Maribavir caused neutrophilia, increased lymphocyte, monocyte and total WBC counts, mild elevated bilirubin, increased absolute and relative adrenal, liver and spleen weights, and mild reversible intestinal mucosal hyperplasia[8].

References:
[1] Levien TL, Baker DE. Maribavir. Hosp Pharm. 2023 Aug;58(4):336-344. doi: 10.1177/00185787221101480.
[2] Kang C. Maribavir: First Approval. Drugs. 2022 Feb;82(3):335-340.
[3] Sun K, Fournier M, Sundberg AK, et al. Maribavir: Mechanism of action, clinical, and translational science. Clin Transl Sci. 2024 Jan;17(1):e13696.
[4] Razonable RR. Current Perspectives on Letermovir and Maribavir for the Management of Cytomegalovirus Infection in Solid Organ Transplant Recipients. Drug Des Devel Ther. 2024 Sep 6;18:3987-4001.
[5] Chou S, Van Wechel L C, Marousek G I. Effect of cell culture conditions on the anticytomegalovirus activity of maribavir. Antimicrob Agents Chemother. 2006 Jul;50(7):2557-2559.
[6] Reitsma J, Terhune S, et al. Inhibition of cellular STAT3 synergizes with the cytomegalovirus kinase inhibitor maribavir to disrupt infection. Antiviral Res. 2014;104:74-85.
[7] Williams S L, Hartline C B, Kushner N L, et al. In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses. Antimicrob Agents Chemother. 2003 Jul;47(7):2186-2192.
[8] Koszalka G W, Johnson N W, Good S S, et al. Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob Agents Chemother. 2002 Aug;46(8):2373-80.

البروتوكول (Protocol)

Cell experiment [1]:

Cell lines

 MRC-5 fibroblasts (human lung fibroblast), ARPE-19 cells (human retinal pigment epithelial), U-373 cells (human astrocytoma)

Preparation Method

 MRC-5, ARPE-19 and U-373 cells were grown to confluence, starved in 0.5% FBS for 2 days, then infected with human cytomegalovirus and treated with 0.1-40μM Maribavir at time of infection, with compound renewed every 24h; viral DNA was measured by qPCR, viral titers by infectious units/plaque assay, proteins by Western blot, and viability by flow cytometry.

Reaction Conditions

 0.1-40μM; 24-96h

Applications

 Maribavir reduced human cytomegalovirus DNA accumulation and viral titers, inhibited pUL97 kinase activity, and together with STAT3 inhibitor S3i-201 caused cleaved caspase-3 and cleaved PARP in infected cells and loss of infected but not uninfected cells.
Animal experiment [2]:

Animal models

 Sprague-Dawley rats

Preparation Method

Rats were orally administered Maribavir at doses of 0-400mg/kg/day via gavage for 28 days. Satellite groups were used for toxicokinetics, reversibility, and histopathology.

Dosage form

0-400mg/kg/day; p.o.; 28 days

Applications

Maribavir caused dose-related reversible increases in neutrophils, lymphocytes, monocytes, and total WBC counts at ≥100mg/kg/day, mild reversible elevations in bilirubin in females at 200 and 400mg/kg/day, increases in absolute and relative adrenal, liver, and spleen weights, and minimal reversible intestinal mucosal hyperplasia at all doses.
References:
[1] Reitsma J M, Terhune S S. Inhibition of cellular STAT3 synergizes with the cytomegalovirus kinase inhibitor maribavir to disrupt infection. Antiviral Res. 2014;104:74-85.
[2] Koszalka G W, Johnson N W, Good S S, et al. Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob Agents Chemother. 2002 Aug;46(8):2373-80.

وثائق المنتج (Product Documents)

Purity:>98.00%Appearance:A solid
COASDSData Sheet

الخصائص الكيميائية (Chemical Properties)

رقم CAS
176161-24-3
المرادفات
1263W94; BW1263W94; GW257406X
الاسم الكيميائي
(2S,3S,4R,5S)-2-((E)-5,6-dichloro-2-(isopropylimino)-2,3-dihydro-1H-benzo[d]imidazol-1-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
SMILES
CC(/N=C1NC2=C(N\1[C@]3([H])[C@](O)([H])[C@](O)([H])[C@](O3)([H])CO)C=C(Cl)C(Cl)=C2)C
الصيغة الجزيئية
C15H19Cl2N3O4
الوزن الجزيئي
376.24
الذوبانية
DMSO : 200 mg/mL (531.58 mM; Need ultrasonic)
التخزين
Store at -20°C
إرشادات عامة
اختر مذيبًا مناسبًا وفقًا لبيانات ذوبانية المنتج. بعد التحضير، قسّم المحلول المخزون إلى أجزاء لتجنب دورات التجميد والذوبان المتكررة.
استخدم المحاليل المخزونة خلال 6 أشهر عند حفظها في -80°C، أو خلال شهر واحد عند حفظها في -20°C.
لتحسين الذوبانية، سخّن الأنبوب إلى 37°C وعرّضه للموجات فوق الصوتية لمدة مناسبة.
شروط الشحن
تُشحن عينات التقييم مع عبوات تبريد. وتُشحن الأحجام الأخرى المتاحة في درجة حرارة الغرفة، أو مع عبوات تبريد عند الطلب.

الحاسبات (Calculators)المولارية / التخفيف / الوزن الجزيئي / تحويل الوحدات / تركيبة داخل الجسم الحي / الذوبانية

g/mol

Reviews

Review for Maribavir

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%